頁籤選單縮合
題 名 | Pathogenetic Role of JAK2 V617F Mutation in Chronic Myeloproliferative Disorders=JAK2-V617F基因突變與慢性骨髓增生症致病機轉之關連性 |
---|---|
作 者 | 徐會棋; | 書刊名 | 中華醫學會雜誌 |
卷 期 | 70:3 2007.03[民96.03] |
頁 次 | 頁89-93+CA17 |
分類號 | 416.66 |
關鍵詞 | 原發性血小板增生症; JAK2基因突變; 慢性骨髓增生症; 真性紅血球增生症; Essential thrombocythemia; JAK2 mutation; Myeloproliferative disorders; Polycythemia vera; |
語 文 | 英文(English) |
英文摘要 | The molecular pathogenesis of chronic myeloproliferative disorders (MPDs) is poorly understood. The hematopoietic progenitor cells of patients with polycythemia vera (PV) or essential thrombocythemia (ET) are characterized by hypersensitivity to hematopoietic growth factors and formation of endogenous erythroid colonies. Recently, 4 groups reported almost simultaneously Janus kinase 2 (JAK2) V617F mutation in more than 80% of PV patients, 30% of patients with ET and in about 50% of patients with idiopathic myelofibrosis. The identification of the JAK2 mutation represents a major advance in the understanding of the molecular pathogenesis of MPDs that will likely permit a new classification and the development of novel therapeutic strategies for these diseases. |
本系統中英文摘要資訊取自各篇刊載內容。